Have You Been Diagnosed with Side Effects Including Gynecomastia After Taking Risperdal?
YOU MAY BE ENTITLED TO COMPENSATION. COMPLETE THE FORM BELOW FOR A FREE CASE EVALUATION BY ONE OF OUR RISPERDAL ATTORNEYS.
OUR RISPERDAL ATTORNEYS ARE CURRENTLY REVIEWING CLAIMS OF INDIVIDUALS WHO HAVE BEEN SUFFERED SEVERE SIDE EFFECTS INCLUDING GYNECOMASTIA AFTER TAKING RISPERDAL
Risperdal attorneys allege Johnson & Johnson hid serious side effects, including gynecomastia. In 2019 a Risperdal lawsuit ended in an $8 billion jury verdict against the company. Prior to that verdict, Johnson & Johnson had previously agreed to settle two Risperdal settlements for $181 million and $2.2 billion to resolve charges that it had promoted the drug for off-label uses.
Risperdal was initially approved by the FDA in 1993 as an antipsychotic medication used to treat schizophrenia and bipolar disorder in adults. Although it not FDA approved for use in children until 2006, allegations regarding improper and illegal marketing for use children in adolescents began to crop up almost immediately after its initial release. In addition to the concerns regarding illegal marketing tactics, a research study published in 1999 found a link between Risperdal and the abnormal development breast tissue (gynecomastia) in young men.
The lawsuits Johnson & Johnson began in 2010 and have picked up steadily. Plaintiffs across the country are alleging improper marketing techniques and a failure on the part of the manufacturers to warn users of potential side effects. The first lawsuit settled on the day of trial for $2.5 million and to date, there have been over 15,000 lawsuits filed nationwide, including 6,600 in a single jurisdiction. Johnson & Johnson has been forced to pay billions of dollars in verdicts, settlements, and government fines for their part in the manufacturing and marketing of Risperdal and with the medication still widely available, those dollar amounts figure to keep escalating as more victims come forward.
If you or a loved one have been adversely affected after being prescribed Risperdal,
call the Risperdal Lawyers at Marin and Barrett, Inc. today at (888) 348-2735 for a free,
no obligation consultation. We can help with your Risperdal lawsuit. You can also fill out our
one-minute questionnaire below to find out whether you have a claim.
Risperdal (also known as risperidone) is an antipsychotic medication used to treat schizophrenia in adults. Originally approved by the FDA in 1993, Risperdal was originally sold and marketed by Janssen, a pharmaceutical subsidiary of Johnson & Johnson. In 2006 the FDA expanded the potential uses of Risperdal and approved it for treatment of schizophrenia in children, bipolar disorder in adults and juveniles, and for behavioral and aggression issues associated with autism in children.
Like many antipsychotics, Risperdal works by blocking the D2 receptor thereby regulating the activity and release of dopamine in the brain. While this can be effective for behavior and psychological issues, blocking dopamine can wreak havoc on the pituitary gland and disrupts a user’s metabolism, causing the release of a hormone known as prolactin. Prolactin has numerous useful and necessary functions, such as telling a woman’s body to make breast milk when she is pregnant or nursing and stimulating the development of breast tissue. Unfortunately, prolactin is also responsible for causing gynecomastia and galactorrhea (abnormal lactation) in adolescent and preadolescent boys. Gynecomastia is the enlargement or swelling of breast tissue in males and is unlikely to resolve even if he ceases use of the medication. Exercise and medicine discontinuation alone are not usually enough to reverse the unwanted effects of gynecomastia; in many cases liposuction will be required to reverse the effects with surgical reduction, or a full mastectomy required in more severe cases.
As is often the case with new drug formulas, the FDA patent for the original risperidone formula patented in 1993 expired in 2003. In June of the following year Janssen lost the exclusive marketing rights to risperidone and the market was flooded with generic equivalents, often for a much lower price. Despite the flood of lawsuits Risperdal is still universally available from a variety of manufacturers in several different forms, including tablets, a long-lasting injection (Risperal Consta), disintegrating tablets (Risperdal M-Tabs), and an oral solution.
As with any medication, Risperdal use may result in a host of side effects ranging from the temporary and mild to severe and potentially permanent. According to the FDA, the most common side effects of Risperdal use are:
– Somnolence or drowsiness
– Abdominal pain
– Nausea and vomiting
In 2005 the FDA required Risperdal and to carry a black box warning because the medication was shown to pose a serious health risks to elderly patients with dementia. A black box warning is the strictest warning imposed by the FDA. A study on the risks of Risperdal use in the elderly showed that the death rate in users over a ten week period was 4.5%, up from 2.6% in those taking placebos; the causes of death varied but were typically the result of infection or hearth failure.
Among the more serious side effects associated with Risperdal use is the development of gynecomastia. Gynecomastia is the enlargement or swelling on the breast tissue in males and is often attribute to a hormonal imbalance. Researchers have known of the association between Risperdal use and the development of gynecomastia as far back as 1999 and the cause becomes more clear once you understand how Risperdal interacts with the body.
Like many antipsychotics, Risperdal works by blocking the D2 receptor, thereby regulating the activity and release of dopamine in the brain. While this can be effective for behavior and psychological issues, blocking dopamine can wreak havoc on the pituitary gland responsible for regulating the release of hormones throughout the body. This can result in a disruption in a user’s metabolism, causing the release of a hormone known as prolactin. Prolactin has numerous useful and necessary functions, such as telling a woman’s body to make breast milk when she is pregnant or nursing and stimulating the development of breast tissue. Unfortunately, at the abnormal levels associated with Risperdal use prolactin is also responsible for causing gynecomastia and galactorrhea (abnormal lactation) in adolescent and preadolescent boys.
Gynecomastia is the enlargement or swelling of breast tissue in males and is unlikely to resolve even if he ceases use of the medication. Exercise and medicine discontinuation alone are not usually enough to reverse the unwanted effects of gynecomastia; in many cases liposuction will be required to reverse the effects with surgical reduction, or a full mastectomy required in more severe cases. In addition to, and in many instances because of, the physical changes, those afflicted with gynecomastia are left to deal with severe ridicule and embarrassment and the potential development of long term psychological issues.
The connection between Risperdal use and the development of gynecomastia is undeniable and is borne our by over two decades worth of clinical research. For instance, a 1999 research study published in The Journal of Clinical Psychopharmacology noted a strong connection between the use of Risperdal and the development of breast tissue in males. In 2015, researchers released an additional study finding that male Risperdal users were nearly four times as likely to develop gynecomastia than non-users; scientists in a separate study reached similar results. Researchers in a separate clinical trial of 1,885 children who took Risperdal found that 43 boys developed gynecomastia, a rate of over 2%. While the physical effects are unmistakable, researchers are also showing that “the psychological may be significant” in instances of men and adolescent boys afflicted with gynecomastia – even after corrective procedures.
The lawsuits against Johnson & Johnson began in 2010 and allege both that the company failed to warn consumers of the potential physical side effects and that it improperly marketed Risperdal to children well before it had been approved by the FDA for adolescent use. The first such lawsuit to reach a resolution involved a young Pennsylvania man who developed significant gynecomastia after taking Risperdal. The case settled at the beginning of trial prior to a jury verdict and for an undisclosed amount in what many throughout the legal community viewed it as vital step forward for victims and as a potential harbinger of future success of Risperdal litigation. That settlement was entered into in 2012, a year that would mark the beginning of serious legal issue for Johnson & Johnson stemming from its manufacture and marketing of Risperdal.
While the terms of that particular settlement are unknown, many of the publicly available dollar figures during that time are significant. Johnson & Johnson was the subject of lawsuits filed across 36 states alleging unlawful marketing techniques that specifically targeted children and ultimately settled for $181 million dollars. There were hundreds of other product liability lawsuits that year all alleging the same improper marketing tactics, several of which were settled. In many instances the dollar figures are unknown, but there were settlements of $327 million, $258 million, and $158 million across three states in 2012 alone.
Those verdicts were just the beginning. Like most areas of the law, every case and situation is different and prior success is by no means a guarantee of wins in the future. There have been instances where Courts have thrown out suits against Johnson & Johnson or cases have been tied up on appeal, but it seems that there is a multimillion dollar plaintiff’s verdict every year. For example:
– 2015: A jury returned a $2.5 million verdict for young man who had developed gynecomastia after taking Risperdal without being adequately warned of the side effects. Testimony in that trial revealed that the company knew that the drug could cause abnormal breast tissue development as early as 2001, but failed to warn the public until 2006, all the while continuing to market it to children.
– 2016: Janssen Pharmaceuticals entered into a settlement with the State of Kentucky agreeing to pay $15.5 million, adequately warn of the risks of taking the drug, and agreeing to no longer market it for uses not approved by the FDA.
– 2017: A $1 million verdict was handed down to plaintiff who had grown breasts at the age of 10 after taking Risperdal to treat a mood disorder.
– 2019: Two separate juries found for a plaintiff who had developed breasts after years of taking the drug as an adolescent. The first jury awarded $1.5 million in damages. A subsequent trial was held to determine punitive damages. That jury came back with an $8 billion verdict in his favor.
The lawsuits each allege that manufacturers knew the risks associated with Risperdal but failed to adequately warn the public, and that the companies engaged in improper marketing for use on children. The suits target several different Risperdal and risperidone manufacturers and a numerous different named brands of Risperdal.
– Risperdal Consta
– Johnson & Johnson
– Janssen Pharmaceuticals, Inc.
– Janssen Research and Development
– Patriot Pharmaceuticals, Inc.
It is not simply plaintiffs who have been adversely affected by using Risperdal. The United States Department of Justice had conducted its own independent investigation into Risperdal marketing practices for years. In 2013 the DOJ concluded its investigation and as a result Johnson & Johnson agreed to pay over $2 billion in fines and penalties to avoid further prosecution. The fines were the largest of the kind ever imposed at the time, but it by no means signaled the end of the legal saga for Johnson & Johnson as they continue to be bombarded lawsuits from civilians injured by Risperdal use.
The U.S. Government and juries across the country have repeatedly found Johnson & Johnson to be liable for its part in failing to warn of the dangers of Risperdal and for marketing the drug improperly, but the company itself has so far admitted no wrongdoing. In fact, Johnson & Johnson still manufactures Risperdal for both adult and adolescent use to this day. With so many innocent people affected nationwide it is unlikely that these lawsuits are going to slow up any time soon.
Did you or a loved one take Risperdal or risperidone to treat bipolar disorder, schizophrenia, or behavioral issues associated with autism and develop gynecomastia or abnormal breast growth or discharge as a result? If so, you may qualify for financial compensation. The verdicts and settlements awarded to victims of deceptive marketing practices and product liability actions have been awarded financial damages for physical harm, pain and suffering, emotional and psychological trauma, and punitive damages.
In the event that you or a loved one has suffered complications or developed breasts after taking Risperdal we here at Marin and Barrett, Inc. are committed to holding the responsible parties accountable and getting you the compensation you deserve and help you get your life back. Call the attorneys at Marin and Barrett, Inc. at (888) 348-2735 today, the consultation is confidential and of absolutely no cost to you.
If you or a loved one developed gynecomastia after taking Risperdal you may have a claim. You may be entitled to financial compensation for damages, including:
- Past, present, and future medical expenses
- Lost wages and lost earning potential
- Pain and suffering
- Loss of consortium
- Punitive damages, if appropriate
In the tragic event that a loved one as died as a result taking Risperdal, you may be eligible to file a wrongful death claim. Of course there is no amount of money that can bring them back or fill the void left by their absence, but a claim may cover funeral and burial expenses, pain and suffering, and any past expenses incurred as a result of their illness.
The Pharmaceutical Industry is an international financial powerhouse, spending $1.2 trillion worldwide and $485 billion in the United States alone in 2018. Do not go it alone, let us fight them for you to get the compensation you rightfully deserve. We work hand in hand with some of the most experienced and respected law firms nationwide and have the resources your case needs to stand toe to toe with pharmaceutical giants.
“Attorney Parrillo listened with compassion. He outlined and explained each step of the legal process in way that was easy to understand. He was very generous with his time and took a genuine interest in my case.”
– Former Client M. B. –
At Marin and Barrett, Inc. we firmly believe that the client’s needs come above all else and have established a fully transparent fee structure to reflect that. We work on a strictly contingency fee basis, meaning that we do not receive anything from you unless we are able to recover money either by settlement or verdict. Regardless of what type of case you have or what is required, you will know everything up front with no surprises. We shoulder the costs of the filing and litigation on your behalf and at no risk to you.
Call our Risperdal attorneys Marin and Barrett, Inc. today (888) 348-2735 to schedule your free consultation, it only takes a few moments and there is no obligation. You can also contact us by completing our one-minute Risperdal questionnaire below.
Disclaimer: Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Past results afford no guarantee of future results and each case is different and is judged on its own merits. Some cases result in no recovery. Costs and expenses will be advanced and reimbursed to us only if you recover. You have no liability for costs or expenses unless a court directs. The choice of a lawyer is an important decision and should not be based solely upon advertisements. Some matters may be referred to other lawyers. From Marin and Barrett’s offices in Rhode Island the firm has represented clients from all parts of Rhode Island, Connecticut, and Massachusetts and has partnered with other law firms to serve clients throughout the U.S.
*Admitted in Rhode Island, Connecticut, Massachusetts and South Carolina
Assisting clients as a Rhode Island Risperdal Lawyer, Connecticut Risperdal Lawyer, and a Massachusetts Risperdal Lawyer
**Admitted in Rhode Island
Assisting clients as a Rhode Island Risperdal Lawyer
***Admitted in Rhode Island and Massachusetts
Assisting clients as a Rhode Island Risperdal Lawyer and a Massachusetts Risperdal Lawyer